Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0044-1791969
Original Article

Efficacy and Safety Profile of Different Schedules of Adjuvant Trastuzumab Therapy among Patients with HER2-Positive Breast Cancer: Real-World Experience from a Tertiary Cancer Center in South India

Nandini Devi Rajan   *
1   Department of Medical Oncology, Malabar Cancer Centre, Moozhikkara (PO), Thalassery, Kannur District, Kerala, India
,
Abhilash Menon
1   Department of Medical Oncology, Malabar Cancer Centre, Moozhikkara (PO), Thalassery, Kannur District, Kerala, India
,
Praveen Kumar Shenoy    *
1   Department of Medical Oncology, Malabar Cancer Centre, Moozhikkara (PO), Thalassery, Kannur District, Kerala, India
,
Manuprasad Avaronnan
2   Department of Medical Oncology, Aster MIMS, Kannur, Kerala, India
,
Sherin Shahana
1   Department of Medical Oncology, Malabar Cancer Centre, Moozhikkara (PO), Thalassery, Kannur District, Kerala, India
,
Bindu Therayangalath 
3   Department of Cancer Registry and Biostatistics, Malabar Cancer Centre, Moozhikkara (PO), Thalassery, Kannur District, Kerala, India
› Author Affiliations Financial Disclosures All the authors declare that none of them have any relevant or material financial interests that relate to the research described in this article.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Zoom Image
Nandini Devi Rajan

One year of adjuvant trastuzumab is the standard of care for HER2-positive breast cancer. In low–middle income countries, delivery of 1-year trastuzumab is challenging due to significant financial burden. Evidence for shorter durations of adjuvant trastuzumab is gaining popularity in this regard. In this study, we compared the effectiveness and safety of 1 year versus shorter durations of adjuvant trastuzumab practiced in our center. In total, 312 patients were included in this analysis. The median age was 52 years. More than two-thirds of patients (67.6%) had stage 2 disease and majority were hormone-receptor-positive (62.5%). The median follow-up duration was 50 months. The 4-year disease-free survival was 97.3%. The 4-year disease-free survival for shorter durations of adjuvant trastuzumab was 98% compared with 96.7% in 1-year trastuzumab therapy group. In univariate analysis, stage at diagnosis was the only factor which had statistically significant association with disease-free survival. In multivariate analysis, none of the variables were found to be predictive of survival. Two patients (0.6%) had significant left ventricular ejection fraction decline.

Shorter durations of adjuvant trastuzumab have comparable 4-year disease-free survival to standard 1-year therapy and is an alternative adjuvant treatment option for HER2-positive breast cancer patients in resource-limited settings.

Keywords

HER2-positive breast cancer - adjuvant trastuzumab - shorter durations of adjuvant trastuzumab

Author's Contribution

N.D.R, P.K.S, and M.A contributed to the project through conceptualization, data curation, formal analysis, investigation, methodology, and both the original draft and review & editing of the writing. A.M and S.S were involved in data curation, formal analysis, investigation, methodology, and writing the original draft, while S.S also participated in writing. B.T contributed by focusing on formal analysis, investigation, methodology, and both the original draft and review & editing of the writing.


Previous Presentation

Part of this study was presented as POSTER at the 21st Annual Conference of Women Cancer Initiative-Tata Memorial Centre at Mumbai on 01–03–2024.


* Both the authors contributed equally to this article.




Publication History

Received: 19 March 2024

Accepted: 21 September 2024

Article published online:
06 November 2024

© 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Slamon D, Eiermann W, Robert N. et al; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365 (14) 1273-1283
    CrossrefPubMedSearch in Google Scholar
  • 2 Ghosh J, Gupta S, Desai S. et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J Cancer 2011; 48 (04) 391-396
    CrossrefPubMedSearch in Google Scholar
  • 3 Nair NS, Gupta S, Ghosh J. et al. Access to HER2-targeted therapy at a tertiary care center in India: An evolution. Indian J Cancer 2022; 59 (03) 375-379
    CrossrefPubMedSearch in Google Scholar
  • 4 Morganti S, Bianchini G, Giordano A, Giuliano M, Curigliano G, Criscitiello C. How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?. ESMO Open 2022; 7 (02) 100428
    CrossrefPubMedSearch in Google Scholar
  • 5 Earl HM, Hiller L, Dunn JA. et al. LBA11 individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer. Med Oncol 2021; 32: S1283
    Search in Google Scholar
  • 6 Conte P, Frassoldati A, Bisagni G. et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Ann Oncol 2018; 29 (12) 2328-2333
    CrossrefPubMedSearch in Google Scholar
  • 7 Gupta N, Verma RK, Gupta S, Prinja S. Cost effectiveness of trastuzumab for management of breast cancer in India. JCO Glob Oncol 2020; 6: 205-216
    CrossrefPubMedSearch in Google Scholar
  • 8 Ansaripour A, Uyl-de Groot CA, Redekop WK. Adjuvant trastuzumab therapy for early HER2-positive breast cancer in Iran: a cost-effectiveness and scenario analysis for an optimal treatment strategy. PharmacoEconomics 2018; 36 (01) 91-103
    CrossrefPubMedSearch in Google Scholar
  • 9 Wiseman RJ, Riddin J, Jugathpal J, Parrish AJ, Ruff P, Blockman M. Adjuvant trastuzumab in early HER2-positive breast cancer: Journeying towards the optimal duration of therapy in South Africa. S Afr Med J 2020; 110 (04) 271-273
    CrossrefPubMedSearch in Google Scholar
  • 10 Gulia S, Kannan S, Badwe R, Gupta S. Evaluation of 1-year vs shorter durations of adjuvant trastuzumab among patients with early breast cancer: an individual participant data and trial-level meta-analysis. JAMA Netw Open 2020; 3 (08) e2011777
    CrossrefPubMedSearch in Google Scholar
  • 11 Ghosh J, Joy Phillip DS, Ghosh J. et al. Survival outcomes with 12 weeks of adjuvant or neoadjuvant trastuzumab in breast cancer. Indian J Cancer 2022; 59 (03) 387-393
    CrossrefPubMedSearch in Google Scholar
  • 12 Swain SM, Macharia H, Cortes J. et al. Event-free survival in patients with early HER2-positive breast cancer with a pathological complete response after HER2-targeted therapy: a pooled analysis. Cancers (Basel) 2022; 14 (20) 5051
    CrossrefPubMedSearch in Google Scholar
  • 13 Hingmire SS, Sambhus MB, Kelkar DS, Joshi S, Parikh PM, Bharath R. Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancer. South Asian J Cancer 2017; 06 (02) 047-50
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Doval DC, Radhakrishna S, Tripathi R. et al. A multi-institutional real world data study from India of 3453 non-metastatic breast cancer patients undergoing upfront surgery. Sci Rep 2020; 10 (01) 5886
    CrossrefPubMedSearch in Google Scholar
  • 15 O'Shaughnessy J, Gradishar W, O'Regan R, Gadi V. Risk of recurrence in patients with HER2+ early-stage breast cancer: literature analysis of patient and disease characteristics. Clin Breast Cancer 2023; 23 (04) 350-362
    CrossrefPubMedSearch in Google Scholar
  • 16 Manuprasad A, Shenoy P, Jones J, Vinin N, Dharmarajan A, Muttath G. Short-course adjuvant trastuzumab in breast cancer: experience from a tertiary cancer center in rural India. Cancer Res Stat Treat 2020; 3 (01) 69
    CrossrefSearch in Google Scholar
  • 17 Onitilo AA, Engel JM, Stankowski RV. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf 2014; 5 (04) 154-166
    CrossrefPubMedSearch in Google Scholar
  • 18 Aggarwal A, Patil P, Rangaraju RR. et al. Cardiotoxicity in patients on trastuzumab in HER2-positive breast cancer – a retrospective analysis from a center in North India. Int J Mol Immuno Oncol [Internet] 2021; 6 (02) 56-60
    CrossrefSearch in Google Scholar
  • 19 Sengar M, Fundytus A, Hopman W. et al. Cancer medicines: what is essential and affordable in India?. JCO Glob Oncol 2022 Jul;(8). Available from: https://ascopubs.org/doi/10.1200/GO.22.00060
    Search in Google Scholar